8.71

10.57% -1.03

After Hours: 8.67 -0.04 -0.46%

Engene Holdings Inc (ENGN)

Overview News Price History Financials Discussions Forecast

Engene Holdings Inc stock is traded at $8.71, with a volume of 635.96K. It is down -10.57% in the last 24 hours and down -1.69% over the past month. enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Previous Close:

$9.74

Open:

$9.65

24h Volume:

635.96K

Relative Volume:

2.10

Market Cap:

$583.48M

Revenue:

Net Income/Loss:

$-103.21M

P/E Ratio:

-1.8934

EPS:

-4.6001

Net Cash Flow:

$-26.70M

1W Performance:

-13.16%

1M Performance:

-1.69%

6M Performance:

+68.15%

1Y Performance:

+54.16%

1-Day Range:

$8.70

$9.72

1-Week Range:

$8.70

$10.34

52-Week Range:

$2.65

$12.25

Engene Holdings Inc Stock (ENGN) Company Profile

Name

Engene Holdings Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(514) 332-4888

Address

4868 RUE LEVY, SUITE 220, SAINT-LAURENT

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ENGN's Discussions on Twitter

Compare ENGN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENGN Engene Holdings Inc	8.71	652.48M	0	-103.21M	-26.70M	-4.6001
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Initiated	Jefferies	Buy
Nov-11-25	Upgrade	Raymond James	Outperform → Strong Buy
Feb-18-25	Initiated	Piper Sandler	Overweight
Feb-14-25	Downgrade	UBS	Buy → Neutral
Dec-23-24	Initiated	H.C. Wainwright	Buy
Nov-27-24	Initiated	Raymond James	Outperform
Nov-18-24	Initiated	JMP Securities	Mkt Outperform
Aug-28-24	Initiated	Oppenheimer	Outperform
Apr-22-24	Initiated	Wells Fargo	Overweight
Apr-15-24	Initiated	Guggenheim	Buy
Mar-28-24	Initiated	UBS	Buy
Mar-08-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	Leerink Partners	Outperform

View All

Engene Holdings Inc Stock (ENGN) Latest News

Mar 04, 2026

Growth Value: Will enGene Holdings Inc stock hit new highs in YEARWeekly Risk Summary & Daily Profit Focused Stock Screening - baoquankhu1.vn

Mar 04, 2026

ENGENE HOLDINGS INC C/WTS 31/10/2028 (TO PUR COM) CL A Stock Quote, Share Price, News and Analysis - Longbridge

Mar 04, 2026

Mar 03, 2026

Trade Report: What analysts say about enGene Holdings Inc Equity Warrant stockWeekly Investment Recap & Fast Gain Stock Tips - baoquankhu1.vn

Mar 03, 2026

[EFFECT] enGene Holdings Inc. SEC Filing - Stock Titan

Mar 03, 2026

Mar 02, 2026

Why is enGene Holdings Inc Equity Warrant stock going upJuly 2025 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn

Mar 02, 2026

enGene (ENGN) Expected to Announce Earnings on Monday - MarketBeat

Mar 02, 2026

Mar 01, 2026

enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 31.5% in February - MarketBeat

Mar 01, 2026

enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 01, 2026

Feb 28, 2026

Earnings Recap: Is enGene Holdings Inc Equity Warrant stock a value trap2025 Buyback Activity & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn

Feb 28, 2026

ENGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Feb 27, 2026

enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference - Yahoo Finance

Feb 27, 2026

Feb 26, 2026

ENGN: Detalimogene shows 62% six-month CR rate in NMIBC, with launch targeted for 2027 - TradingView

Feb 26, 2026

Feb 24, 2026

Market Trends: How does enGene Holdings Inc compare to its peersJuly 2025 Retail & Safe Entry Point Identification - baoquankhu1.vn

Feb 24, 2026

Institution Moves: Is enGene Holdings Inc Equity Warrant stock a value trapJuly 2025 Levels & Consistent Growth Stock Picks - baoquankhu1.vn

Feb 24, 2026

CEO Moves: Is OCUL subject to activist investor interestMarket Volume Report & Safe Capital Growth Stock Tips - baoquankhu1.vn

Feb 24, 2026

Feb 23, 2026

ENGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 23, 2026

enGene Holdings Inc. Warrants Stock Forecast Summary - Meyka

Feb 23, 2026

Feb 21, 2026

Aug Update: What are the analyst revisions for enGene Holdings IncIs FACT stock a good investment in YEARJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn

Feb 21, 2026

Aug Weekly: How does enGene Holdings Inc compare to its peersTrade Exit Report & Fast Exit/Entry Strategy Plans - baoquankhu1.vn

Feb 21, 2026

Feb 20, 2026

Should I add enGene Holdings Inc. stock to my portfolioJuly 2025 Highlights & Daily Market Momentum Tracking - mfd.ru

Feb 20, 2026

enGene to Highlight Genetic Medicine Pipeline at Series of Investor Conferences - TipRanks

Feb 20, 2026

enGene to Participate in Upcoming Investor Conferences - FinancialContent

Feb 20, 2026

EnGene Files $400 Million Mixed Shelf - marketscreener.com

Feb 20, 2026

Feb 19, 2026

EnGene Holdings files for mixed shelf of up to $400 million - marketscreener.com

Feb 19, 2026

Cormorant Asset Management (ENGN) reports 5.97% passive stake in enGene - Stock Titan

Feb 17, 2026

Feb 16, 2026

Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN) - Insider Monkey

Feb 16, 2026